Resource impact statement

No significant resource impact is anticipated

NICE has recommended pemigatinib as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the population size is small. It is estimated around 50 people per year are eligible for treatment with pemigatinib. Current treatment is active symptom control with or without chemotherapy. There may be additional costs incurred for FGFR2 testing which is not currently done for this population group.

Pemigatinib has a discount that is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: